Chen Zhang, Peng Tu, Xiangyu Jia, Yuanfeng Xia, Biao Lu, Fanglong Yang, Siqin Wang, Lei Jin
{"title":"作为治疗卵巢癌的驱动蛋白 KIF18A 抑制剂的新型环己烯基衍生物的设计、生物学特性和发现","authors":"Chen Zhang, Peng Tu, Xiangyu Jia, Yuanfeng Xia, Biao Lu, Fanglong Yang, Siqin Wang, Lei Jin","doi":"10.1021/acsmedchemlett.4c00383","DOIUrl":null,"url":null,"abstract":"A novel class of kinesin KIF18A inhibitors were discovered through modification of the clinical compound AMG650. Structure–activity relationship (SAR) study led to the discovery of compound <b>16</b> with an alkenyl motif, a highly potent KIF18A inhibitor, which displayed a favorable pharmacological profile and excellent efficacy in a mouse model of an OVCAR-3 xenograft tumor. Oral administration of <b>16</b> can induce a dose-dependent antitumor efficacy in the OVCAR-3 model without significant reduction in body weight. Compound <b>16</b> showed potential as a candidate for the clinical treatment of ovarian cancer.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"31 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer\",\"authors\":\"Chen Zhang, Peng Tu, Xiangyu Jia, Yuanfeng Xia, Biao Lu, Fanglong Yang, Siqin Wang, Lei Jin\",\"doi\":\"10.1021/acsmedchemlett.4c00383\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A novel class of kinesin KIF18A inhibitors were discovered through modification of the clinical compound AMG650. Structure–activity relationship (SAR) study led to the discovery of compound <b>16</b> with an alkenyl motif, a highly potent KIF18A inhibitor, which displayed a favorable pharmacological profile and excellent efficacy in a mouse model of an OVCAR-3 xenograft tumor. Oral administration of <b>16</b> can induce a dose-dependent antitumor efficacy in the OVCAR-3 model without significant reduction in body weight. Compound <b>16</b> showed potential as a candidate for the clinical treatment of ovarian cancer.\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acsmedchemlett.4c00383\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.4c00383","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer
A novel class of kinesin KIF18A inhibitors were discovered through modification of the clinical compound AMG650. Structure–activity relationship (SAR) study led to the discovery of compound 16 with an alkenyl motif, a highly potent KIF18A inhibitor, which displayed a favorable pharmacological profile and excellent efficacy in a mouse model of an OVCAR-3 xenograft tumor. Oral administration of 16 can induce a dose-dependent antitumor efficacy in the OVCAR-3 model without significant reduction in body weight. Compound 16 showed potential as a candidate for the clinical treatment of ovarian cancer.
期刊介绍：
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
